Papillary Carcinoma — Trials

Papillary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

206 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 51
Recruiting: 20
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01116648	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	active not recruiting	Phase 1 / Phase 2	155	National Cancer Institute (NCI)NIH	1	Jul 14, 2026	clinicaltrials
NCT05122546	CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer	active not recruiting	Phase 1	31	City of Hope Medical CenterOTHER	1	Mar 5, 2026